Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Sawai Group in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $48.17.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Sawai Group. This N/A consensus rating has held steady for over two years.
Sawai Pharmaceutical Co., Ltd. engages in the manufacture and sale of prescription pharmaceutical products. Its products include cardiovascular drugs, antihyperlipidemic agents, diabetes, anticancer drugs, and over-the-counter drugs. It operates through the Japan and United States segments. The Japan segment sells manufactured pharmaceuticals to domestic sales companies, wholesale stores and other pharmaceutical manufacturers, as well as directly to medical institutions. The United States segment comprises of holding companies that manages subsidiaries and sell manufactured pharmaceuticals to wholesale stores in the United States. The company was founded by Hanpei Sawai and Noyo Sawai on April 1, 1929 and is headquartered in Osaka, Japan.
Read More